type here...

CATEGORIES

Discover Drugs

LATEST

123Page 1 of 3

TRENDING

EDITORS CHOICE

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

Medika Life -
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

How COVID and the Power of Now Killed Scientific Peer Review

Gil Bashe, Medika Life Editor -
How long do or should clinical trials take – well, it depends – but often years. Science takes time. It demands rigor and objectivity. It’s not a “now” pursuit.

FDA Approves Drug Combination for Treating Mesothelioma

Medika Life -
First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers SILVER SPRING, Md., Oct. 2, 2020 /PRNewswire/ -- Today, the U.S. Food...

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories